Acquired resistance to EGFR-TKI
Continuation of gefitinib with CT at PD NOT improve PFS neither OS
Gefitinib
+
Cisplatin / Pem
Max 6 cycles
Gefitinib until
PD
Placebo +
Cisplatin / Pem
Max 6 cycles
Placebo until PD
1:1 randomisation
•
PD on Gefitinib by RECIST
criteria
•
Measurable stage IIIB / IV
disease
•
ECOG 0-1
•
activating
EGFR
mutations
N=265
Soria, Lancet Oncol 2015; Mok, ESMO 2016
PFS:
5.4
vs.
5.4
HR 0.86, p=0.273
OS:
13.4
vs.
.
19.5
HR 1.44, p=0.016
IMPRESS Phase III Trial
